Tekla Life Sciences Investors Paid Distribution
June 30 2022 - 10:10AM
Business Wire
On June 30, 2022, Tekla Life Sciences Investors paid a
distribution of $0.35 per share. It is currently estimated that
this distribution is derived from net realized long-term capital
gains and return of capital or other capital source. The
composition of this and subsequent distributions may vary from
quarter to quarter because it may be materially impacted by future
realized gains and losses on securities. The aggregate of the net
unrealized appreciation of portfolio securities and net realized
gains on sale of securities is $27,738,231, of which $20,963,340
represents net unrealized appreciation of portfolio securities.
The following table sets forth the estimated amounts of the
current distribution, paid on June 30, 2022, and the cumulative
distributions paid this fiscal year-to-date from the following
sources: net investment income, net realized short-term capital
gains, net realized long-term capital gains and return of capital
or other capital source. The Fund estimates that it has distributed
more than its income and net realized capital gains; therefore, a
portion of your distribution may be a return of capital. A return
of capital may occur, for example, when some or all the money that
you have invested in the Fund is paid back to you. A return of
capital distribution does not necessarily reflect the Fund’s
investment performance and should not be confused with ‘yield’ or
‘income’. All amounts are expressed per common share.
Current Distribution
Percentage Breakdown of
Current Distribution
Total Cumulative Distributions
for the Fiscal Year to Date1
Percentage Breakdown of the
Total Cumulative Distributions for the Fiscal Year to Date1
Net Investment Income
$0.0000
0%
$0.0000
0%
Net Realized ST Cap Gains
$0.0000
0%
$0.0342
3%
Net Realized LT Cap Gains
$0.0544
16%
$0.5962
51%
Return of Capital or Other Capital
Source
$0.2956
84%
$0.5296
46%
TOTAL (per common share):
$0.3500
100%
$1.1600
100%
The table below includes information relating to the Fund’s
performance based on its NAV for certain periods.
Average annual return at NAV for the
period from April 30, 2017 through April 30, 2022
3.22%
Annualized current distribution rate
expressed as percentage of NAV as of April 30, 2022
8.83%
Cumulative total return at NAV for the
fiscal year, through April 30, 20222
-21.84%
Cumulative fiscal year-to-date
distribution rate expressed as a percentage of NAV as of April 30,
20221
7.32%
You should not draw any conclusions about the Fund’s investment
performance from the amount of this distribution or from the terms
of the Fund’s managed distribution policy.
The amounts and sources of distributions reported in this press
release are only estimates and are not being provided for tax
reporting purposes. The actual amounts and sources of the amounts
for tax reporting purposes will depend upon the Fund’s investment
experience during the remainder of its fiscal year and may be
subject to changes based on tax regulations. The Fund will send you
a Form 1099-DIV for the calendar year that will tell you how to
report these distributions for federal income tax purposes.
Tekla Life Sciences Investors (NYSE: HQL) is a closed-end fund
that invests in companies in the healthcare industry.
Tekla Capital Management LLC, the Fund’s investment adviser, is
a Boston, MA based healthcare-focused investment manager with
approximately $3.3 billion of net assets under management as of
March 31, 2022. Tekla also serves as investment adviser to Tekla
Healthcare Investors (NYSE: HQH), Tekla Healthcare Opportunities
Fund (NYSE: THQ) and Tekla World Healthcare Fund (NYSE: THW),
closed-end funds that invest in companies in the healthcare and
life sciences industries. Information regarding the Funds and Tekla
Capital Management LLC can be found at www.teklacap.com.
Destra Capital Advisors is the Fund’s marketing and investor
support services agent. Please contact Destra Capital Advisors at
HQL@destracapital.com or call (877) 855-3434 if you have any
questions regarding HQL.
- The Fund’s current fiscal year began on October 1, 2021.
- Cumulative total return at NAV is the percentage change in the
Fund’s NAV and includes all distributions and assumes the
reinvestment of those distributions for the period of September 30,
2021 through April 30, 2022.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220630005632/en/
Destra Capital Advisors HQL@destracapital.com (877) 855-3434
abrdn Healthcare Opportu... (NYSE:THQ)
Historical Stock Chart
From Apr 2024 to May 2024
abrdn Healthcare Opportu... (NYSE:THQ)
Historical Stock Chart
From May 2023 to May 2024